Avania Appoints Recognized CRO and MedTech Industry Leader, Jason Monteleone, as New President and CEO
4.9.2024 16:00:00 EEST | Business Wire | Press release
Avania — the leading global MedTech clinical research organization (CRO) providing product development, market access, and clinical contract research services — today announced the appointment of Jason Monteleone as president and CEO, effective September 2, 2024. Monteleone succeeds Sapna Hornyak, who had served as president and CEO since 2019. Under Hornyak’s leadership, Avania developed a strong, integrated global MedTech platform, which Jason will further enhance through growth initiatives, deeper therapeutic specialization, and innovation to solidify Avania’s position as a leading MedTech CRO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904978746/en/
Jason Monteleone, newly appointed president and CEO of Avania. (Photo: Business Wire)
With over 25 years of experience in the CRO, medical device, and life sciences sectors, Monteleone brings deep expertise in driving growth, innovation, and operational excellence. From 2017 until 2021, Monteleone was CEO of Clinipace, a global midsize CRO, where revenue increased 65% under his tenure before being acquired by dMed in April 2021. While chief financial officer at Theorem Clinical Research, a global midsize CRO focused on pharmaceutical and medical device studies, revenue and head count doubled before being acquired by Chiltern International in September 2015. Most recently, Monteleone served as president of Ancillare, a global provider of ancillary supplies and equipment for clinical trials.
Additionally, Monteleone is a board member and audit chair for the Drug Information Association (DIA), the leading global multidisciplinary life science membership association driving collaboration in drug, device, and diagnostic development in pursuit of a healthier world. Monteleone founded Pivotal Financial Consulting, advising investors and companies in clinical research on acquisitions, growth strategies, and innovation. He was also director of finance at VIASYS Healthcare, a publicly traded medical device company, before its acquisition by Cardinal Health and merger into CareFusion.
“I am honored to join Avania and lead this exceptional team at such an exciting time in our industry,” said Monteleone. “Avania partners with some of the world’s most innovative companies in numerous therapeutic areas such as cardiovascular, neurology, orthopedics, and aesthetics to name a few. The privilege to assist our customers in developing life-changing products for patients is the reason we are passionate about what we do, driving us to innovate, collaborate, and deliver excellence in every project.”
Todd Pope, chairman of Avania’s board, added, “I look forward to working closely with Jason as he leads Avania to continue making a positive impact for our customers, employees, and the MedTech community. The executive team and board are excited about the future as we bring Avania to the forefront of innovation and operational excellence.”
Edouard Pillot, partner and co-head of Astorg Mid-Cap, the majority shareholder in Avania, remarked, “We are excited to welcome Jason as Avania’s new CEO. His exceptional track record of driving growth and operational excellence, combined with his experience in scaling businesses, make him the perfect leader for Avania’s next phase. With deep expertise in the CRO and MedTech industries, Jason will drive innovation and deliver distinctive solutions for our customers. We look forward to seeing Avania create long-term value for its stakeholders under his leadership.”
About Avania
Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904978746/en/
Contacts
Holli Kroeker
+1 308-338-2358
pr@scorrmarketing.com
Jasmine Saba
+1 214 418 3201
jasmine.saba@avaniaclinical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*13.11.2026 00:07:00 EET | Press release
The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release
VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever launched. Every account represents a real person with a verified heartbeat. They have real goals, challenges, and achievements. T
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 18:00:00 EET | Press release
The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and quantum chemistry to embed safety into chemical design from the outset. Adaptive catalytic systems: Led by the Max Planck Insti
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 17:00:00 EET | Press release
Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical applications. As India continues to play a critical role in supplying medicines to patients around the world, pharmaceutical manufacturers face increasing demands for quality, regulatory compliance,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom